These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3758431)

  • 1. [Aluminum associated bone disease in patients undergoing long-term hemodialysis].
    Hino M; Yamamoto I; Shigeno C; Aoki J; Torizuka K; Iwamoto N; Yamazaki S; Fukuda T; Kondo M; Yamamoto N
    Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):724-36. PubMed ID: 3758431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminium-induced bone disease in uremic rats: effect of deferoxamine.
    Jablonski G; Klem KH; Danielsen CC; Mosekilde L; Gordeladze JO
    Biosci Rep; 1996 Feb; 16(1):49-63. PubMed ID: 8861540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferoxamine for the diagnosis and treatment of aluminum-associated osteodystrophy.
    Charhon S; el Yafi S; Gaillard M; Beruard M; Janin G; Accominotti M; Traeger J; Meunier PJ
    Contrib Nephrol; 1988; 64():160-9. PubMed ID: 3180823
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.
    Mathias R; Salusky I; Harman W; Paredes A; Emans J; Segre G; Goodman W
    J Am Soc Nephrol; 1993 Jun; 3(12):1938-46. PubMed ID: 8338926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aluminum in renal osteodystrophy].
    Zhu P; Wang GY; Yu YF; Zhu P
    Zhonghua Nei Ke Za Zhi; 1993 Mar; 32(3):176-8. PubMed ID: 8222983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
    Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
    Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal osteodystrophy and its possible correction in patients on chronic hemodialysis].
    Rozental' RL; Babarykin DA; Tikhomirova TE; Il'inskiĭ IM; Chernevskis KhK
    Ter Arkh; 1986; 58(1):105-8. PubMed ID: 3961679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone aluminum and histomorphometric features of renal osteodystrophy.
    Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW
    J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of aluminum-associated bone disease in long-term hemodialysis patients.
    Iwamoto N; Ono T; Yamazaki S; Fukuda T; Kondo M; Yamamoto N; Hiratake Y; Masugi Y; Kubo Y; Hino M
    Nephron; 1986; 42(3):204-9. PubMed ID: 3945360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of renal osteodystrophy in hemodialysis patients.
    DeVita MV; Rasenas LL; Bansal M; Gleim GW; Zabetakis PM; Gardenswartz MH; Michelis MF
    Medicine (Baltimore); 1992 Sep; 71(5):284-90. PubMed ID: 1522804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
    Tzamaloukas AH
    Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis].
    Palmieri P; Albertazzi A; Cappelli P; Di Paolo B
    G Clin Med; 1981 Jul; 62(7):443-60. PubMed ID: 7308629
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal osteodystrophy in patients on hemodialysis for more than 10 years.
    Piraino BM; Rault R; Dominguez JH; Puschett JB
    Miner Electrolyte Metab; 1986; 12(5-6):390-6. PubMed ID: 3807834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis].
    Albertazzi A; Palmieri PF; Del Rosso G; Spisni C; Evangelista M
    Minerva Nefrol; 1980; 27(4):631-3. PubMed ID: 7254690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.